Page 3 - Kai Shi News Today : Breaking News, Live Updates & Top Stories | Vimarsana

First-line furmonertinib can prolong progression-free survival, compared with gefitinib, in EGFR-mutated, advanced non-small cell lung cancer.

Kai shiEuropean lung cancer congressYuan kai shiChinese academyMedical sciencesPeking union medical collegeLung cancer congress